{"disease":{"id":"hormone-receptor-positive-breast-carcinoma","name":"hormone receptor positive breast carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06058377","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":3680,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06805812","title":"Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study","phase":"","overall_status":"RECRUITING","enrollment_count":3500,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT04314401","title":"National Cancer Institute \"Cancer Moonshot Biobank\"","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1600,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04379570","title":"Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1167,"lead_sponsor_name":"Alliance for Clinical Trials in Oncology","has_results":false},{"nct_id":"NCT05568472","title":"Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":565,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT06112613","title":"Mobile Health for Adherence in Breast Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT03845166","title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":325,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT02003209","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":315,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07222215","title":"PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":297,"lead_sponsor_name":"Kristina A. Fanucci","has_results":false},{"nct_id":"NCT05173103","title":"Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"University of Milano Bicocca","has_results":false},{"nct_id":"NCT05194072","title":"A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":250,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT04802876","title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":184,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT06144944","title":"Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":160,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT04505826","title":"A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":153,"lead_sponsor_name":"Olema Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06534125","title":"Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer","phase":"NA","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04316117","title":"Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":138,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT03251378","title":"A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":true},{"nct_id":"NCT05868226","title":"PRE-I-SPY Phase I/Ib Oncology Platform Program","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":124,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false},{"nct_id":"NCT06463626","title":"Real-life Treatment Patterns With Cyclin-dependent Kinase Inhibitors in Advanced Breast Cancer in Portugal - REVEAL Study","phase":"","overall_status":"COMPLETED","enrollment_count":121,"lead_sponsor_name":"Novartis","has_results":false},{"nct_id":"NCT06106282","title":"Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)","phase":"","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT07341503","title":"The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06338644","title":"Palbociclib in Metastatic Breast Cancer: Gene Polymorphism-based Study in Egyptian Patients.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":100,"lead_sponsor_name":"Helwan University","has_results":false},{"nct_id":"NCT07460752","title":"Evaluation of Alternative Site Goserelin Acetate Injection for Ovarian Function Suppression (OFS) in Local and Locally Advanced Premenopausal Hormone Receptor Positive Breast Cancer Patients","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":98,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04553770","title":"Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Jonsson Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT06179303","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT07042581","title":"A Study of Revaree Plus in People With Breast Cancer","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT05501704","title":"ETHAN - ET for Male BC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Jose Pablo Leone","has_results":false},{"nct_id":"NCT05327608","title":"Neoadjuvant Breast Cancer Time Restricted Eating","phase":"NA","overall_status":"RECRUITING","enrollment_count":55,"lead_sponsor_name":"Thomas Jefferson University","has_results":false},{"nct_id":"NCT04726332","title":"Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT02668666","title":"Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Oana Danciu, MD","has_results":true},{"nct_id":"NCT04305834","title":"Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":43,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT07112053","title":"A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"University of Washington","has_results":false},{"nct_id":"NCT05464810","title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT07044310","title":"5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT02152943","title":"Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06224673","title":"ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Laura Huppert, MD, BA","has_results":false},{"nct_id":"NCT07137416","title":"Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05098210","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT03939897","title":"Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":24,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04797728","title":"Elacestrant in Preoperative Setting, a Window of Opportunity Study","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"SOLTI Breast Cancer Research Group","has_results":false},{"nct_id":"NCT05488145","title":"A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy","phase":"NA","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT04720664","title":"Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Georgetown University","has_results":true},{"nct_id":"NCT04876378","title":"Impact of Breast Cancer Treatment on Joint Health, Cartilage Composition, and Bone Structure in the Knee and Hand","phase":"","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04481113","title":"Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"OHSU Knight Cancer Institute","has_results":false},{"nct_id":"NCT04789668","title":"Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05554354","title":"Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04305236","title":"Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"University of California, Irvine","has_results":true},{"nct_id":"NCT06590558","title":"Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04756505","title":"Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04602117","title":"ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"QuantumLeap Healthcare Collaborative","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}